Overview

PTX-200 and Carboplatin in Ovarian Cancer

Status:
Terminated

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Prescient Therapeutics, Ltd.

Treatments:

Carboplatin